Telegraph

7x24 real-time news feed, auto refreshBeijing Time：

All A·Important B·Normal #stem cells ✕
A
[Four-connected Nanhua Bio: Cell therapy-related technologies and products are still in the research and development stage, and no innovative drugs have been launched or entered the clinical trial stage] On September 22, Nanhua Bio (000504.SZ) issued a stock trading risk warning announcement stating that the company's current main business is biomedicine and energy conservation and environmental protection. Among them, the biomedicine segment mainly provides customers with testing and storage services for biological resources such as stem cells and immune cells. It also cooperates with a number of clinical research institutions to provide them with cell preparation, testing and other services that meet clinical research requirements. The company's cell therapy-related technologies and products are still in the research and development stage, and no innovative drugs have been launched or entered the clinical trial stage. The energy-saving and environmental protection segment is mainly engaged in lithium carbonate business, scrap steel renewable resources and supporting processing and sales.
#clinical trial#stem cells#cell#A-share announcement express#A-share risk warning announcement09-22 18:20
B
[Merck’s new formulation of Premin® Letermovir Tablets (II) is launched in China] On September 16, Merck announced that its new non-nucleoside cytomegalovirus (CMV) inhibitor Premin®’s new dosage form Letermovir Tablets (II) has been officially launched in China It is marketed in China for the prevention of cytomegalovirus infection and cytomegalovirus disease in adults and pediatric recipients 6 months and older and weighing ≥6kg who are seropositive for cytomegalovirus (CMV) who have received allogeneic hematopoietic stem cell transplantation (HSCT) [R+].
#stem cells#Gene#cell#Virus#medicine09-16 17:06
B
[Shi4 Pharmaceutical Group: Letermovir Injection received drug production registration approval] On September 10th, Shi4 Pharmaceutical Group issued a voluntary announcement that the company has obtained the drug production registration approval document from the China National Medical Products Administration for Letermovir Injection (12ml:240mg). This product belongs to Category 4 chemical drugs and is deemed to have passed the consistency evaluation. Letermovir injection is mainly used for cytomegalovirus (CMV) seropositive adult recipients who have received allogeneic hematopoietic stem cell transplantation to prevent cytomegalovirus infection and cytomegalovirus disease. It needs to be used in combination with basic infusion and should be used in the perioperative period of hematopoietic stem cell transplantation. Relying on the existing advantages of basic infusion, the Group continues to improve the therapeutic injection product pipeline, and this approval further enriches the perioperative product portfolio.
#stem cells#Chemical#Gene#cell#Virus#generic drugs#chemicals#Hong Kong stock trends09-10 12:04